News | March 20, 2026
Epigenica expands into Japan via PrimeTech partnership
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The initial consideration for the transaction is US$ 12 million
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The company announced positive topline data from the Phase 3 ADorable-1 trial
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Subscribe To Our Newsletter & Stay Updated
